Guidelines for Multiple Myeloma 2012: status of lenalidomide in the treatment of refractory / relapsed disease

Abstract

This article summarizes current views on the subject of treatment resistant / relapsed multiple myeloma with lenalidomide. The favorable effect of early treatment on the basis of randomized trials is unquestionable.

Worse results in the Czech Republic caused by a lack of strengths and in particular the existence of so-called "STOP rules", which compliance is still required.

Keywords

• lenalidomide
• therapy
• relapse
• progression
• overall survival
• toxicity